Innovative Oncology Focus EPICS Therapeutics specializes in developing small molecule drugs targeting RNA epigenetic mechanisms in cancer, positioning them as a promising partner for biotech firms and research organizations seeking novel oncology treatment solutions.

Recent Funding Growth With an infusion of €12 million in Series A funding and new CEO appointment, the company is strategically expanding its pipeline and capabilities, indicating potential for partnership and investment opportunities to advance their drug development efforts.

Strategic Collaborations EPICS has a history of partnerships, including with Ogeda, which suggests openness to collaborative ventures and licensing deals, opening avenues for co-development and technology licensing agreements.

Early Stage Market As a company with a revenue of less than 1 million dollars and a small team, EPICS presents opportunities for early-stage partnering with organizations interested in innovative pipeline assets or in providing strategic funding and support.

Focused R&D Pipeline Their emphasis on RNA epigenetic mechanisms in cancer offers a niche area for biotech and pharma companies seeking targeted therapeutics, making EPICS a potential partner for licensing and co-creation of next-generation cancer treatments.